JP5892666B2 - 細胞死促進剤 - Google Patents

細胞死促進剤 Download PDF

Info

Publication number
JP5892666B2
JP5892666B2 JP2014052612A JP2014052612A JP5892666B2 JP 5892666 B2 JP5892666 B2 JP 5892666B2 JP 2014052612 A JP2014052612 A JP 2014052612A JP 2014052612 A JP2014052612 A JP 2014052612A JP 5892666 B2 JP5892666 B2 JP 5892666B2
Authority
JP
Japan
Prior art keywords
less
cell death
cyclin
pp2a
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014052612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015174843A5 (enExample
JP2015174843A (ja
Inventor
野島　博
博 野島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Priority to JP2014052612A priority Critical patent/JP5892666B2/ja
Publication of JP2015174843A publication Critical patent/JP2015174843A/ja
Publication of JP2015174843A5 publication Critical patent/JP2015174843A5/ja
Application granted granted Critical
Publication of JP5892666B2 publication Critical patent/JP5892666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2014052612A 2014-03-14 2014-03-14 細胞死促進剤 Active JP5892666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014052612A JP5892666B2 (ja) 2014-03-14 2014-03-14 細胞死促進剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014052612A JP5892666B2 (ja) 2014-03-14 2014-03-14 細胞死促進剤

Publications (3)

Publication Number Publication Date
JP2015174843A JP2015174843A (ja) 2015-10-05
JP2015174843A5 JP2015174843A5 (enExample) 2015-11-12
JP5892666B2 true JP5892666B2 (ja) 2016-03-23

Family

ID=54254341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014052612A Active JP5892666B2 (ja) 2014-03-14 2014-03-14 細胞死促進剤

Country Status (1)

Country Link
JP (1) JP5892666B2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144863A1 (en) * 2017-02-04 2018-08-09 Gordon Erlinda M Cyclin g1 inhibitors and related methods of treating cancer
WO2023196620A1 (en) * 2022-04-08 2023-10-12 Delta Next-Gene, LLC Combination cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016209A1 (en) * 1995-11-01 1997-05-09 University Of Southern California Expression of cyclin g1 in tumors
NZ521070A (en) * 2000-03-02 2004-07-30 Univ Southern California Mutated cyclin G1 protein

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144863A1 (en) * 2017-02-04 2018-08-09 Gordon Erlinda M Cyclin g1 inhibitors and related methods of treating cancer
US11325958B2 (en) 2017-02-04 2022-05-10 Delta Next-Gene, LLC Cyclin G1 inhibitors and related methods of treating cancer
US12173041B2 (en) 2017-02-04 2024-12-24 Delta Next-Gene, LLC Cyclin G1 inhibitors and related methods of treating cancer
WO2023196620A1 (en) * 2022-04-08 2023-10-12 Delta Next-Gene, LLC Combination cancer therapy

Also Published As

Publication number Publication date
JP2015174843A (ja) 2015-10-05

Similar Documents

Publication Publication Date Title
Qian et al. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy
JP6956159B2 (ja) 腫瘍溶解性アデノウイルスによる脳癌の処置方法
Liu et al. Phosphorylation of the BNIP3 C-terminus inhibits mitochondrial damage and cell death without blocking autophagy
Bouquet et al. The loss of γH2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage
De Grève et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Han et al. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition
Michiue et al. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma
JP5893078B2 (ja) インビボでの神経膠芽腫細胞の浸潤を阻害するｃｄ９５活性の中和
US20160130663A1 (en) Method for predicting response to cancer treatment
Gupta-Saraf et al. HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus
Park et al. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
CN107530433A (zh) 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
Novak et al. The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma models
JP5892666B2 (ja) 細胞死促進剤
Suzuki et al. Live-cell imaging visualizes frequent mitotic skipping during senescence-like growth arrest in mammary carcinoma cells exposed to ionizing radiation
US20210100752A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
AU2018301504B2 (en) Method for managing pain
US20240189336A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
Renier et al. Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy
Wu et al. A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells
US10335481B2 (en) Gene-modified measles virus for tumor treatment use
Adachi et al. Hypersensitivity to cisplatin after hRev3 mRNA knockdown in head and neck squamous cell carcinoma cells
US11897925B2 (en) Treatment of homologous recombination deficient cancers
KR100740342B1 (ko) Ｐｋｃ 델타의 ｈｓｐｂ1 결합부위를 포함하는 암 치료용조성물
Niemöller et al. Targeting death-receptors in radiation therapy

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150821

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150821

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160219

R150 Certificate of patent or registration of utility model

Ref document number: 5892666

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250